HER2 Support Group Forums - View Single Post - Combined ER and HER-targeted therapy in breast cancer treatment

Laurel · 06-06-2009, 05:22 AM

Yes, and RAD001 seems to decrease incidence of endometrial hyperplasis caused by Tamoxifen! It does seem that it should prompt Oncs to consider adding Tykerb post Herceptin completion at least for an extended period while SERMs or AIs are being employed to downregulate E.R./P.R.

Let's keep an eye out for a clinical trial for Tykerb in the adjuvent setting for early Her2 and ER or PR + B.C. I, for one, would sign on.

06-06-2009, 05:22 AM	#5
Laurel Senior Member Join Date: May 2008 Location: Hershey, PA. Live The Sweet Life! Posts: 2,005	Yes, and RAD001 seems to decrease incidence of endometrial hyperplasis caused by Tamoxifen! It does seem that it should prompt Oncs to consider adding Tykerb post Herceptin completion at least for an extended period while SERMs or AIs are being employed to downregulate E.R./P.R. Let's keep an eye out for a clinical trial for Tykerb in the adjuvent setting for early Her2 and ER or PR + B.C. I, for one, would sign on. __________________ Smile On! Laurel Dx'd w/multifocal DCIS/IDS 3/08 7mm invasive component Partial mast. 5/08 Stage 1b, ER 80%, PR 90%, HER-2 6.9 on FISH 0/5 nodes 4 AC, 4 TH finished 9/08 Herceptin every 3 weeks. Finished 7/09 Tamoxifen 10/08. Switched to Femara 8/09 Bilat SPM w/reconstruction 10/08 Clinical Trial w/Clondronate 12/08 Stopped Clondronate--too hard on my gizzard! Switched back to Tamoxifen due to tendon pain from Femara 15 Years NED I think I just might hang around awhile....